Drug Trial Radar · NCT03523585
DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]
Last checked: Nov 19, 2026Latest source record: Feb 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
608
Actual
Start
Aug 1, 2018
Primary completion
Jun 30, 2022
Study completion Dec 23, 2025
Sponsor
- Lead sponsor
- Daiichi SankyoDaiichi Sankyo (DSNKY)
- Sponsor type
- Industry
- Collaborators
- Daiichi Sankyo Co., Ltd.; AstraZeneca
- First posted
- May 14, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will compare DS 8201a to standard treatment. Participants must have HER2 breast cancer that has been treated before. Their cancer: * cannot be removed by an operation * has spread to other parts of the body
Conditions
- Breast Cancer
Interventions
Trastuzumab deruxtecanDrug
DS-8201a is sterile lyophilized powder reconstituted into a sterile aqueous solution (100 mg/5 mL) to be administered as intravenous (IV) dose
CapecitabineDrug
Investigator's choice Standard of Care when combined with trastuzumab or lapatinib
LapatinibDrug
Investigator's choice Standard of Care when combined with capecitabine
TrastuzumabDrug
Investigator's choice Standard of Care when combined with capecitabine
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival (PFS) Based on Blinded Independent Central Review (BICR) in Participants With HER2-positive, Unresectable and/or Metastatic Breast Cancer Participants Previously Treated With Trastuzumab EmtansineTime frame: Baseline up to 46 months postdose
Locations
227 sites in 15 countries. Site status is shown where the registry gives one.
Ironwood Cancer Research Centers
Chandler, Arizona
UCLA Hematology Oncology - Main Site
Los Angeles, California
Pacific Cancer Care
Monterey, California
Sharp Memorial Hospital
San Diego, California
Innovative Clinical Research Institute
Whittier, California
Smilow Cancer Hospital at Yale New Haven
New Haven, Connecticut
Washington Cancer Institute
Washington D.C., District of Columbia
Florida Cancer Specialists-Broadway
Fort Myers, Florida
Piedmont Cancer Institute, PC
Atlanta, Georgia
Kapiolani Medical Center for Women and Children/Univ of HI
Honolulu, Hawaii
Loyola University Health System
Maywood, Illinois
Community Hospital
Munster, Indiana
Norton Cancer Institute
Louisville, Kentucky
Maine Center for Cancer Medicine
Scarborough, Maine
University of Maryland
Baltimore, Maryland
Beth Israel Deaconess Medical Center
Boston, Massachusetts
Dana Farber Cancer Institute
Boston, Massachusetts
Henry Ford Hospital
Detroit, Michigan
Cornell-Beshore Cancer Institute
Joplin, Missouri
Saint Luke's Cancer Institute
Kansas City, Missouri
Health Midwest Ventures Group, Inc d/b/a HCA MidAmerica Division, LLC
Kansas City, Missouri
Washington University
St Louis, Missouri
North Shore Hematology Oncology Associates, PC
East Setauket, New York
Memorial Sloan-Kettering Cancer Center (MSKCC) - New York
New York, New York
University of Cincinnati Medical Center
Cincinnati, Ohio
Cleveland Clinic Main Campus
Cleveland, Ohio
The Ohio State University
Columbus, Ohio
Dayton Physicians, LLC
Kettering, Ohio
Abramson Cancer Center
Philadelphia, Pennsylvania
Allegheny General Hospital
Pittsburgh, Pennsylvania
UPMC Cancer Center
Pittsburgh, Pennsylvania
Tennessee Oncology, PLLC Chattanooga
Chattanooga, Tennessee
The West Clinic
Germantown, Tennessee
SCRI - Tennessee Oncology
Nashville, Tennessee
UT Southwestern Medical Center
Dallas, Texas
MD Anderson Cancer Center
Houston, Texas
The Methodist Hospital Research Institute
Houston, Texas
The University of Texas Health Science Center at Tyler
Tyler, Texas
Community Cancer Trials of Utah
Ogden, Utah
Virginia Cancer Specialists, PC
Fairfax, Virginia
Showing 40 of 227 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.